期刊
CLINICAL GENITOURINARY CANCER
卷 14, 期 4, 页码 265-270出版社
CIG MEDIA GROUP, LP
DOI: 10.1016/j.clgc.2015.12.030
关键词
Biomarkers; Drug resistance; Neoplasms metastasis; Prostatic neoplasms; Receptors androgen; Taxoids
资金
- Instituto de Salud Carlos III Subdireccion General de Evaluacion y Fomento de la Investigacion [PI12/01226, PI15/00676]
- Hospital Clinic de Barcelona (Premi Fi de Residencia Emili Letang)
- Sanofi
Prostate cancer is a molecularly heterogeneous disease, and mechanisms of action of taxanes and potential mechanisms of resistance are not clearly defined. Taxanes are microtubule-stabilizing agents resulting in the slowing or blocking of mitosis at the metaphase-anaphase transition and induction of apoptotic cell death. Taxanes also can inhibit androgen receptor pathway. To date, several factors have been associated with taxane resistance, including alterations in tubulin, the effect of drug efflux pumps, and the dysfunctional regulation of signaling pathways that may be involved in resistance to therapy. Preclinical and clinical data support the distinct activity of cabazitaxel in prostate cancer that may overcome resistance to prior taxanes or hormonal therapies. It is challenging to define the most adequate therapeutic sequence for each patient. Moreover, the identification of molecular markers of resistance may help to select patients for specific therapies. (C) 2015 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据